UCLA MEDICAL DEVICE PARTNERING CONFERENCE © 2016 Regents of the University of California Contents

INDUSTRY INVENTORS INVESTORS

ING CONFERENCE TNER PAR 4TH ANNUAL ICE EV D AL IC ED M A TUESDAY MARCH 8, 2016 L C CNSI—UCLA CAMPUS U

#UCLAMedDevice

Conference Program

9:30 am REGISTRATION/NETWORKING

9:45 am WELCOME—Emily Waldron Loughran

MORNING SESSION

11:15 am FACULTY PRESENTATIONS Kalyanam Shivkumar | Reggie Edgerton | Nader Pouratian | Jeffrey Ardell | Itzhak Fried

12:30 pm LUNCH

AFTERNOON SESSION

2:45 pm UCLA BUSINESS OF SCIENCE CENTER

3:05 pm NETWORKING BREAK

3:30 pm UCLA STARTUP PITCHES HyTek Medical | KASH Scientific | Hypothermia Devices

4:00 pm NETWORKING/EVENT CLOSE

Speaker Profiles 2

Startup Company Profiles 9

UCLA Available Medical Device Technologies 10

Neuromodulation and Recording Technologies 11

Cardiovascular Devices 13

Device Materials 14

Diagnostic Tools 16

Orthopedic Devices and Biomechanics 16

Radiation Therapy and Oncology 17

Sensors and Patient Monitoring Devices 17

Surgical Tools 19

Conference Sponsors and Partner Organizations 21

Contact Information 22 Michael Ackermann, Ph.D. Jeffrey L. Ardell, Ph.D., Anthony Arnold Vice President, Neurostimulation FAHA President and CEO Allergan, Plc Professor of Medicine/Cardiology SetPoint Medical Director, UCLA Neurocardiology Research Center of Excellence UCLA Cardiac Arrhythmia Center

Michael is currently Vice President, Dr. Ardell is the founding Director of the Tony is President and CEO of SetPoint Neurostimulation for Allergan, Plc, UCLA Neurocardiology Research Center Medical, an early stage medical and most recently CEO of Oculeve, of Excellence and on faculty in the UCLA device company developing a novel Inc., which was acquired by Allergan Cardiac Arrhythmia Center. Previously, implantable bioelectronic medicine in August 2015. He has eleven years he was Professor of Biomedical Sciences therapy to improve the lives of patients of experience in medical technology at the Quillen College of Medicine in with debilitating inflammatory diseases development in both academic and Johnson City, Tennessee. Dr. Ardell such as Crohn’s and rheumatoid arthritis. industrial settings in the fields of received his doctorate at the University Tony brings 18 years of experience in ophthalmology, chronic pain and of Washington, with post-doctoral the development and commercialization movement disorders. He received a B.E. training at Michigan State University and of high-tech medical devices. Prior to degree, magna cum laude, in biomedical at Loyola University of Chicago. He is a joining SetPoint, he founded Synapse engineering from Vanderbilt University, fellow of the American Heart Association Strategy and provided consulting M.S. and Ph.D. degrees in biomedical and is one of the principal investigators services for leading device firms, FDA engineering from Case Western Reserve in the field of neurocardiology. Dr. Ardell and professional organizations to help University, is a graduate of the Stanford has served on multiple national research commercialize products, develop public University Biodesign fellowship, and and advisory committees for the National health campaigns, assess opportunities Vision Research Fellow at Stanford. Institutes of Health and the American and develop strategic plans. Prior He has numerous patents and peer- Heart Association. to Synapse, Tony served as VP of reviewed publications. His laboratory has been at the forefront Marketing for Boston Scientific where in defining the neural circuits of the he launched the Harmony® Bionic Ear. cardiac nervous system in normal Tony was also Director of Marketing at and pathological states and how Medtronic, responsible for the industry they regulate cardiac electrical and leading StealthStation® neuro-navigation mechanical function. Recent work platform. Prior to Medtronic, Tony held from his group has demonstrated a variety of positions in marketing and that targeting select elements within R&D with Smith + Nephew. this neural network, using bioelectric Tony holds a Bachelors in Mechanical therapies, can lead to efficacious Engineering and graduated the UCLA results in select cardiac disease states, Anderson School of Management including atrial arrhythmias, myocardial executive program for medical marketing. infarction, and congestive heart failure.

2 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Allen W. Burton, M.D. Rafael Carbunaru, Ph.D. Roy Doumani Medical Director of Neuromodulation, Vice President, Executive Director, Movement Disorders and Pain Research & Development UCLA Business of Science Center VP of Clinical Affairs Boston Scientific Neuromodulation Professor, UCLA David Geffen St. Jude Medical School of Medicine

Dr. Allen W. Burton is a Board- Rafael Carbunaru leads the Research Roy Doumani is a professor at the Certified Anesthesiologist, with added and Development Neuromodulation David Geffen School of Medicine at the Certification in Pain Medicine. He was Division for Boston Scientific University of California, Los Angeles formerly the Chairman of the Department Corporation located in Valencia, CA. (UCLA) and Executive Director of the of Pain Medicine at the University of He is focused on developing a portfolio UCLA Business of Science Center. He Texas MD Anderson Cancer Center of neuromodulation products and serves as Co-Chairman of the Zhejiang from 2000–2011. He helped train technologies, and creating a culture California NanoSystems Institute in the many pain fellows during that time. of meaningful innovation and high People’s Republic of China (PRC) and He then spent 4 years with Houston performance. His team has developed is a Director of the first joint venture Pain Associates, where he directed breakthrough products in spinal cord bank in the PRC, Xiamen International clinical research and participated in stimulation for the treatment of chronic Bank of which he has an equity position. many clinical trials. Dr. Burton joined pain and deep brain stimulation for Mr. Doumani has been involved with St. Jude Medical in September of 2015 movement disorders. Rafael’s mission numerous financial institutions: Director as Medical Director of Neuromodulation, is to transform lives through innovative of First Los Angeles Bank, Chairman of Movement Disorders and Pain, and VP of medical technologies. First Interstate Bank of Hawaii, Chairman Clinical Affairs. of World Trade Bank, Los Angeles, Prior to this role, Rafael was the Executive Director of HonFed Bank, Dr. Burton obtained his Bachelor of Research & Development Director and a Founder of Agensys, Inc. He is Science at the University of Notre Dame, for Emerging Indications. He led the presently Chairman of Neural Analytics Medical Doctorate at Baylor College development of micro stimulation and and a Founder and Director of Kite of Medicine, and residency at Brigham MRI-compatible technologies as well as Pharma. He earned a degree from and Women’s Hospital, Harvard Medical supported clinical trials in migraine and UCLA in Business and Finance and School. Dr. Burton has published more overactive bladder, among others. a law degree from the University of than 50 peer-reviewed articles in Rafael holds a Ph.D. and M.Sc. in Southern California. the pain literature and authored two Biomedical Engineering (with emphasis in textbooks. Dr. Burton teaches and neurostimulation and electromagnetism) lectures nationally and internationally. from Case Western Reserve University He has served in leadership roles and an Electrical Engineering degree in pain societies, and serves on from Universidad Simon Bolivar many editorial boards. His practice (Venezuela). He currently holds over 50 includes the use of pharmacologic, U.S. and International patents. interventional, and behavioral pain management techniques. Dr. Burton is an active researcher and has started a pharmaceutical company in the pain space, Vapogenix (www.vapogenix.com). Dr. Burton lives with his wife and three sons in Houston. He spends his small amount of free time running, cycling, swimming, and watching sports.

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 3 V. Reggie Edgerton, Ph.D. Jeffrey Erb Itzhak Fried, M.D., Ph.D., Distinguished Professor, UCLA Senior Director of Strategy, FACS Neurosurgery, Integrative Biology and Business Development and Professor, UCLA Neurosurgery Physiology, and Neurobiology Alliance Management Professor, UCLA Psychiatry and Director, UCLA Neuromuscular Medtronic PLC, Neuromodulation Biobehavioral Sciences Research Laboratory Member, UCLA Brain Research Institute

Dr. V. Reggie Edgerton received his Jeff Erb is Senior Director of Itzhak Fried is the Director of the Ph.D. in Exercise Physiology from Strategy, Business Development and Adult Epilepsy Surgery Program in Michigan State University, Masters from Alliance Management for Medtronic the Department of Neurosurgery at University of Iowa and B.S. from East Neuromodulation. Jeff is responsible UCLA as well as the Co-Director of Carolina University. He is the Director of for leading portfolio strategy including the Seizure Disorder Center. The the Neuromuscular Research Laboratory the annual strategic planning process; epilepsy surgery program at UCLA is and Distinguished Professor of the identifying, investing in and acquiring recognized as a world leader in this Departments of Integrative Biology external opportunities of strategic field. He is the Director of the Cognitive and Physiology, Neurobiology and importance; and managing external Neurophysiology Laboratory which is Neurosurgery and a member of the Brain partnerships. recognized worldwide as the leader in Research Institute at UCLA. He has been studies of human cognition at the level of Jeff joined Medtronic in 2002 in teaching and conducting research at the single neuron, using the opportunity Medtronic’s Corporate Development UCLA for over 45 years. His research of intracranial electrodes implanted in group where he was responsible is focused on how the neural networks epilepsy patients for surgical evaluation. for driving mergers and acquisitions in the lumbar spinal cord of mammals, More recently, his lab has been at the across the company. Jeff also served including humans, regain control of forefront of the study of deep brain as the Chief Financial Officer for two standing, stepping and voluntary control stimulation for enhancement of cognitive of Medtronic’s portfolio companies, of fine movements after paralysis, and function in general and memory in including Medtronic’s joint venture how these motor functions can be particular. with Genzyme, MG Biotherapeutics, in modified by chronically imposing which he also served as the Medtronic activity-dependent interventions Collaboration Manager. In 2006, Jeff after spinal cord injury. Many of these moved to Medtronic’s CardioVascular projects are being performed with business where he was Director of national and international collaborators Pricing and Contracts, Director of and he has published over 480 peer- Strategy and Director of Marketing. In reviewed papers on topics in this area. 2010, Jeff moved to Neuromodulation Dr. Edgerton is also the President where he continues to serve. He has and Chairman of the Board for undergraduate degrees in economics NeuroRecovery Technologies Inc. and business administration from the University of Pittsburgh and an M.B.A. from the University of Michigan.

4 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Norm Gitis, Ph.D. Paul M. Grand Tom Kelly, M.Sc., MIE, Ph.D. Managing Partner, Lymo Ventures Managing Director, Head of Division MedTech Committee, Pacific Coast Office Industrial, Lifesciences & Consumer Life Science Angels RCT Ventures Enterprise Ireland Screening Committee, Band of Angels

Norm Gitis obtained his Ph.D. in Grand has more than twenty-five Tom Kelly is Head of Enterprise Ireland’s Engineering from the USSR Academy of years experience in venture capital Industrial, Lifesciences and Consumer Sciences in Moscow. Upon immigration and the founding and management of Division. Enterprise Ireland is the to the U.S., he was a visiting professor at early-stage companies in technology government body with the responsibility MIT until IBM moved him to San Jose. and healthcare. He is responsible for for the development of Ireland’s sourcing RCT’s investments in medical indigenous and natural resource Norm founded and ran two profitable devices and representing RCT on the based industries. test-instrumentation companies, Center boards of its portfolio companies. Since for Tribology, Inc. in Mountain View He has responsibility for developing 1990, Grand has built, operated, recruited (1994–2000) and CETR in Campbell and implementing the organisations’ management and raised financing for (2000–2011). He was twice named by strategies in Life Sciences, Engineering, eight high technology, medical device the Business Journal the CEO of Top and related sectors. He is recognised and biotechnology companies. 20 Fastest Growing Private Companies as a “thought leader” on manufacturing in Northern California. Upon successful Grand is actively involved in programs to and is a member of key government fora exit, Norm was VP of Bruker, a leading encourage innovation and technology looking at the future of manufacturing manufacturer of test instrumentation for commercialization and is a frequent in Ireland. life sciences and other applications. speaker, moderator and panelist at He is based at Enterprise Ireland’s healthcare conferences. He serves as Norm has authored over 150 scientific offices in East Point Plaza, Dublin 3, and producer and emcee for the MedTech papers, three books and over two is a member of its Executive Committee, Innovator accelerator and competition, dozen patents, chaired and organized and is Chairman of its Finance, Job which identifies and rewards outstanding over three dozen international scientific Expansion and Capital Investment early-stage medical device companies. conferences. Committees. He is also a member of the Grand is on the Oversight Committees Governing Body of Dublin Institute of Over the past three years, Norm has for the Coulter Translational Research Technology and a member of the Board been pursuing his passion of helping Partnership Programs at USC and of NIBRT (The National Institute for med-tech start-ups with funding, IP and University of Washington. He has Bioprocessing Research and Training). business development. His investment lectured, served as a reviewer for proof portfolio includes twelve med-tech of concept and commercialization- Prior to taking up his current assignment startup companies. Norm chairs a device focused funding programs, and he was senior manager within the screening committee of Life Science mentored students and scientists at Scaling Division, leading a team of Angels and serves on a screening numerous universities, including UCLA, specialists in business development committee of the Band of Angels, both Stanford, USC, UCSF, University of and innovation management, working in Silicon Valley. Utah, the Keck Graduate Institute and directly with a select group of fast growth University of Colorado. Grand served as client firms. an investment advisor to the LARTA NIH Earlier in his career he was Head Commercialization Assistance Program of Enterprise Ireland’s Technology for SBIR program awardees. Development Division, assisting firms to adopt best manufacturing and business practices and fostering innovation particularly through new product and process R&D and technology transfer.

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 5 Emily Waldron Loughran Juan-Pablo Mas J. Casey McGlynn Senior Director of Licensing Partner Partner UCLA OIP-ISR Action Potential Venture Capital Wilson Sonsini Goodrich & Rosati

Emily Loughran joined UCLA’s OIP-ISR Juan-Pablo is a partner at Action J. Casey McGlynn formed the Life in 1994 as a technology transfer officer. Potential Venture Capital in Palo Alto, Sciences Group at Wilson Sonsini Currently, as the Senior Director of CA, and invests in companies that are Goodrich & Rosati in 1990. It is Licensing, she manages the licensing pioneering bioelectronic medicines and a nationally recognized practice and patent prosecution groups, and other enabling technologies. Juan- representing startups and emerging oversees the office’s large portfolio Pablo is on the Board of Directors of growth companies in the life sciences of invention disclosures, patents, and SetPoint Medical. He was previously field—Medical Devices, Digital Health, license agreements. Emily started in an investor at Lightstone Ventures Diagnostics and Biotechnology. intellectual property administration at the and Morgenthaler Ventures, where he Mr. McGlynn has formed, sold and taken City of Hope Medical Center where she focused on therapeutic medical devices, public many of the most important was the Technology Transfer Manager mobile health, and biopharmaceutical medical device companies formed responsible for patenting and licensing investments. There he served as a during the last 30 years. Mr. McGlynn activities. Emily holds an MBA from USC Board Observer at Ardian (acquired by has extensive hands-on experience and a BS from UC Berkeley. Medtronic), Twelve (acquired Medtronic), in helping entrepreneurs form, build, Holaira, Miramar Labs, Cabochon fund and sell their companies. He Aesthetics (acquired by Ulthera/Merz), has close working relationships with and SetPoint Medical. an unparalleled list of entrepreneurs, doctors, investors, engineers and Prior to investing, Juan-Pablo led efforts managers in the life sciences field. in R&D and Strategy in Medtronic’s CardioVascular Division, including Pipeline Strategy, White-Space expansion, Business Development, and M&A integration efforts. He was named “Medtronic Inventor of The Year” in 2008, and has 30+ patents, granted or pending. Juan-Pablo also launched Effient (prasugrel) during his tenure on the Global Brand Strategy team at Eli Lilly & Co. Juan-Pablo earned an MBA from Stanford Graduate School of Business. He also conducted research in the Neurology Department at Stanford Hospital, while completing an M.S. in Electrical Engineering at Stanford University. There he worked on biometric signal processing applications such as neural-prosthetics, EMG-driven feedback systems, and improved ICD detection algorithms. Juan-Pablo currently serves on the Board of Directors of SetPoint Medical, and the Boston-based non-profit, InnerCity Weightlifting.

6 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Jennifer McMahon, M.Sc., Widya Mulyasasmita Nader Pouratian, M.D., B.Sc. New Ventures Ph.D., FAANS, FACS Associate Johnson & Johnson Innovation Associate Professor Seroba Life Sciences UCLA Neurosurgery

Jennifer McMahon joined the team Widya is part of the New Ventures Dr. Pouratian is an Associate Professor of of Seroba Life Sciences in 2011. She team at Johnson & Johnson California Neurosurgery and Radiation Oncology graduated from University College, Innovation Center, where she and affiliated faculty in Bioengineering Dublin with an honours degree in supports deals and collaborations and Neuroscience. He earned his Pharmacology in 2010. Jennifer then across consumer, medical device and bachelors, medical, and Ph.D. degrees entered a Master’s degree programme pharmaceutical sectors. at UCLA before completing his in Biotechnology and Business to further neurosurgical training and specialty Widya comes to Johnson & Johnson her interest in the interface of biomedical training in functional neurosurgery at from McKinsey & Company, where she science with commercialisation. Having the University of Virginia. He has broad was a management consultant advising placed first in her Master’s degree yet in-depth training in both functional clients in healthcare and other industries in 2011, Jennifer then joined Seroba neurosurgery and the acquisition and on corporate strategy, lean operations, Life Sciences’ Investment Team as comprehensive analysis of multiple and organizational health topics. Prior to an Investment Analyst. Jennifer is a brain mapping modalities and has McKinsey, Widya worked at GE Ventures member of and Dublin-hub Ambassador published extensively in the field of Healthcare and she also co-founded a of the Thousand Network (formerly the human brain mapping, comparing human medical device startup called Lap IQ, Sandbox network), a global community brain mapping signals from multiple where she served as Chief Scientist for “exceptional innovators.” In October modalities, including functional MRI, developing biodegradable wound 2015 Jennifer was recognised as one optical imaging, evoked potentials, closure devices. of Ireland’s “Top 30 Under 30,” shaping electrocortical stimulation mapping, the future of business in the country. Widya is a bioengineer with expertise electrocorticography, local field She guest-lectures on venture capital in biomaterials, drug delivery, and potentials, and single unit recordings. at University College Dublin, Trinity regenerative medicine. She received her As a neurosurgeon, neuroscientist, College Dublin and the Royal College B.S. in Materials Science Engineering and bioengineer, he has the unique of Surgeons, Ireland. Jennifer was and Bioengineering from the University perspective and training to integrate promoted to Senior Analyst in 2014. of California Berkeley and her Ph.D. in these fields and take advantage Bioengineering from Stanford University of the unparalleled opportunities Seroba Life Sciences is a European life where she was a Siebel Scholar. presented by neurosurgery to study sciences venture capital firm, focused human brain function and design on investing in breakthrough healthcare novel neurotechnologies. His current technologies that promise to improve focus is understanding the network lives and make a difference worldwide. basis of disease and designing novel Headquartered in Ireland, they work with network-based interventions to address some of Europe’s best entrepreneurs neurological and psychiatric disease. developing innovative medical devices, diagnostics and therapeutic drugs.

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 7 Kalyanam Shivkumar, M.D., Lei (Eric) Tang, Ph.D., J.D. Ph.D., FHRS, FACC Managing Partner Professor of Medicine, Radiology & TitanMed Capital Bioengineering Director, UCLA Cardiac Arrhythmia Dr. Tang is the Managing Partner of Center & EP Programs TitanMed Capital, an international Director & Chief, Interventional healthcare venture capital firm with Cardiovascular Programs, UCLA offices in Beijing, Hangzhou, and Research Faculty, Molecular, Cellular Los Angeles. The firm, together with and Integrative Physiology IDP its strategic partners, provides funding and industry resources to emerging Dr. Shivkumar is a physician scientist companies focused on medical devices, who serves as the director of the biotechnology, and healthcare services. UCLA Cardiac Arrhythmia Center & Prior to co-founding TitanMed Capital, EP Programs since its establishment Dr. Tang co-founded ZD Medical, a in 2002. His field of specialization is medical device company focusing on interventional cardiac electrophysiology, providing medical imaging as well as and his research work relates to ophthalmic solutions to addressing mechanisms of cardiac arrhythmias in unmet healthcare needs. Dr. Tang holds humans and the neurovisceral sciences. a Ph.D. degree in Biochemistry and Cell Dr. Shivkumar and his colleagues are Biology and J.D. degree, and worked actively involved in human mechanistic for many years as a patent attorney for studies, development of new intellectual major law firms in the U.S. before co- property, and medical technology for founding ZD Medical. cardiovascular therapeutics. He serves as a section editor of the society journal “Heart Rhythm,” associate editor of “Trends in Cardiovascular Medicine,” is on the editorial board of the journals “JACC,” “PACE,” “JACC-Clinical EP,” and is a peer reviewer for several basic science and clinical journals and for the NIH in evaluating cardiac arrhythmia and neuroscience research. Dr. Shivkumar has received several teaching awards and has been nominated to serve the board of examiners for Clinical Cardiac Electrophysiology of the ABIM (American Board of Internal Medicine). He has been elected to the membership of the American Society of Clinical Investigation (ASCI) and serves as the institutional representative of UCLA for the ASCI. Dr. Shivkumar received his M.D. from the University of Madras, India in 1991 and his Ph.D. from UCLA in 2000.

8 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Startup Company Profiles

Founded in 2012 by UCLA physicians PneumoGel is a hydrogel product Hypothermia Devices, Inc. (“HTD”) and engineers, HyTek Medical developed at UCLA and delivered on designs and manufactures digitally developed the sOLVe Tube (Simplified the surface of the lung during lung controlled and non-invasive cooling/ One Lung Ventilation for Everyone) biopsies to seal the needle tract. heating devices for a wide range of to transform the space of One Lung PneumoGel serves to limit the rate of medical applications, including devices Ventilation and satisfy an unmet pneumothorax from lung biopsies, a for the treatment of patients who suffer need. Packed with both evolutionary common and expensive complication a cardiac arrest. HTD’s heat exchange and revolutionary innovations, this which can be seen in up to 40% of system is a substantial improvement novel device solves ALL the clinical patients. Medicare data have shown over current hypothermia devices shortcomings of the current double a 10-fold increase in the cost of lung as it is the first to use thermoelectric lumen tubes without requiring new biopsy to $35K when complicated by coolers as direct cooling agents to physician training or increasing cost. pneumothorax. KASH Scientific Inc. create hypothermia. Our devices are HyTek Medical is poised to disrupt a has licensed PneumoGel, the delivery capable of cooling and heating tissue space dominated by multi-billion dollar system and the process from UCLA, and very quickly and with a level of precision companies. is in the process of performing preclinical that, until now, has been impossible to animal trial. PneumoGel is patented in attain. Moreover, unlike current systems, the U.S., Europe, China and India. KASH HTD’s system is: (1) battery operated; (2) Scientific is looking for strategic partners portable; (3) compact; and (4) lightweight. in field to fund the animal trial and FDA It can be used both by first responders 510K clearance. and in the hospital setting. Current cooling devices use technology that has existed for decades to cool patients. HTD’s mission is to bring medical cooling into the digital age.

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 9 UCLA Medical Device Technologies Available for Licensing

10 UCLA MEDICAL DEVICE PARTNERING CONFERENCE efficiency with <20ms tracking time, and Wireless Wearable Big Data Neuromodulation and start-up voltages as low as 65mV. A 645µW Brain-Machine Interface regulated output power was harvested from Recording Technologies the head of a rat (0.83cm2 surface area) In order to improve the investigation, with an implanted TEH device. The new diagnosis, and treatment of brain activity, A Highly-Efficient Near-Field TEH device achieves a 7.9x improvement UCLA researchers have designed a user- Wireless Power Transfer System in regulated power density and represents friendly brain-machine interface (BMI) that that is Immune to Distance and/or the first fully autonomous energy harvesting consists of an implanted recording-and- platform for energy-starved applications. transmitting module, a wearable receiving- Coupling-Coefficient Variations and-forwarding module, and a mobile Power transfer technologies transfer UCLA Case No. 2015-245 post-processing unit. Whereas previous power optimally at one specific distance. LEAD INVENTOR: Dejan Markovic systems designed to monitor neural activity As a result, product designs may require Patent Status: Pending are limited in data transfer rates and use a constant distance and therefore include physically connected wires, this newly things like magnets in cochlear products designed BMI can wirelessly transmit data to align the implant and external earpiece. Method, Apparatus, and Circuit to at an unprecedented rate of ∼1 Giga-bit/ UCLA researchers from the Department Monitor Cardiac Disease, Control second. This BMI could support research of Electrical Engineering have developed Arrhythmias and Function by investigating brain activity mapping, the a wireless power transfer system that can Modulating the Nervous System diagnosis of brain abnormalities, and the deliver stable power to the load over a large development of new treatments to prevent Most heart conditions are characterized by range of distances. Additionally, the circuitry or cure brain-related illnesses. detectable abnormalities of electrical (neural) is mainly built at the power transmitter side heart function, but currently there exists UCLA Case No. 2014-495 of the system, allowing the receiver end (e.g. very limited technology for the prolonged biomedical implant) to remain very small. LEAD INVENTOR: Wentai Liu active monitoring and early stage treatment Patent Status: Pending UCLA Case No. 2016-390 of these abnormalities. Dr. Kalyanam LEAD INVENTOR: Asad Abidi Shivkumar’s technology is a neural recording and analysis system for the diagnosis, Saturation-Tolerant Patent Status: Pending continuous monitoring, and treatment of Electrophysiological Recording heart disease. The system records heart Interface A High Dynamic-Range Sensing neurons using electrodes implanted in or Weak electrophysiological input signals Front-End for Neural Signal around the heart wherein the electrodes (EEG, ECG, EMG) are often detected by Recording Systems can deliver neuro-modulatory stimulation to digitizing them using a large voltage gain correct for functional abnormalities. The ability for neuromodulation systems to in order to achieve a low background noise simultaneously stimulate and record deep UCLA Case No. 2015-093 level. However, in noisy environments, the brain areas is currently only achievable LEAD INVENTOR: Kalyanam Shivkumar loud signals from motion artifacts, unrelated in bulky wall-plugged systems that can biological signals, or man-made interferers Patent Status: Pending capture tiny signals in the presence of large saturate the input signal and prevent their stimulation artifacts. Implantable devices EVENT SPEAKER detection. Researchers at UCLA have are low power, but have inadequate input designed an electrophysiological signal signal range. UCLA researchers from the Wireless Implantable System to processing device that can measure EEG, Department of Electrical Engineering have Restore Memory ECG, and EMG signals with high sensitivity designed a technology that achieves in noisy environments that would otherwise Traumatic brain injury (TBI) may cause sufficient signal range and power levels drown out weak signals. An on-chip system both anterograde and retrograde memory that are suitable for implants. This enables has been developed that shows a 20x impairment. While implantable deep concurrent sensing and stimulation in natural improvement for saturation tolerance over brain stimulation (DBS) systems are FDA- living environment, thereby greatly improving existing systems of similar power, noise, approved for the treatment of Parkinson’s the ability to provide timely and efficacious and area. disease and epilepsy, there are currently therapeutic response. no interventional therapies for memory UCLA Case No. 2014-404 UCLA Case No. 2016-100 restoration in TBI patients. UCLA researchers LEAD INVENTOR: Dejan Markovic LEAD INVENTOR: Dejan Markovic have developed a wireless, implantable Patent Status: Pending DBS system that delivers electrical brain Patent Status: Pending stimulation via specially designed electrodes (UCLA Case No. 2014-287) in order to Silicon Microsystems for Autonomous Thermoelectric restore and enhance the memory of patients High-Throughput Analysis of Energy-Harvesting Platform for suffering from TBI. Neural Circuit Activity Biomedical Sensors UCLA Case No. 2014-959 Functional MRI (fMRI) and electro To make thermoelectric energy harvesters LEAD INVENTOR: Itzhak Fried encephalography (EEG) techniques can (TEH) a truly autonomous energy source provide coarse-grained pictures of neuronal Patent Status: Pending for size-constrained, wireless biomedical activity in the brain; however, they are unable sensors and eliminate the need for batteries, EVENT SPEAKER to provide information on rapidly changing it has been necessary to drastically improve activity of single neurons, which is key to their energy density and conversion unraveling how the brain codes information. efficiency. UCLA researchers from the UCLA researchers in the Department of Department of Electrical Engineering have Neurobiology have developed a unique developed an autonomous energy source for electrode array capable of simultaneously implantable biosensors by developing a TEH mapping neural activity from two or more that can operate with a 68% end-to-end peak brain structures. This technology addresses

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 11 major technical obstacles of recording Systems, Devices, and Methods Intracranial Implantable single neuron activity and expands on the for Treating Medical Disorders Mechanical Device for Housing potential for neuronal monitoring by allowing and Conditions through Neurostimulators or Drug Infusion single-cell-resolution measurements of activity from numerous networked brain Stimulation of Multiple Nerves Traditional implantable brain stimulators structures. In addition to enhanced recording Vagus nerve stimulation is ordinarily and drug infusion pumps require stimulation performance, these new electrode array- practiced by surgically implanted electrical generators and drug pumps to be implanted probes will be more cost-effective to nerve stimulator systems, with all the in the patient’s chest, with wires or catheter manufacture, as well as smaller and hence attendant risks of surgery adjacent to major tubes running up through the neck. UCLA less invasive. blood vessels and of anesthesia. Trigeminal researchers in the Department of Surgery nerve stimulation, as developed at UCLA, have developed a novel device described as UCLA Case No. 2013-039 involves the placement of electrodes on the Skull Universal Indweller for Generators LEAD INVENTOR: Sotiris Masmanidis the surface of the face. Here, a polycranial (SUIG) to house cranial energy or drug Patent Status: Pending nerve stimulation system includes externally delivering apparatuses. A rigid mechanical applied electrodes placed on the skin over enclosure houses an implantable electrical Method of Cardiovascular Control the desired nerve dermatomes (e.g., skin pulse generator (IPG) or drug infusion pump in the thickness of a removed portion of with Non-Invasive Stimulation of of the ear and/or ear canal) where gentle electrical signals are used to stimulate the the skull, eliminating the need for wires and Specific Regions of the Central nerve to treat individuals experiencing tubes tunneling through the neck. Enclosures Nervous System epilepsy, depression, fatigue, tinnitus, or can readily accommodate a range of Researchers at UCLA have developed a other conditions. commercially available IPGs and pumps. novel method of stimulating brain regions to UCLA Case No. 2012-639 UCLA Case No. 2008-616 control blood pressure and heart rate. The LEAD INVENTOR: Scott Krahl technology encompasses a non-invasive LEAD INVENTOR: Ian Cook electrophysiological method of modulating Patent Status: Pending Patent Status: Pending central nervous system activity in order Pub. No. 20130030368 to control cardiovascular function. Using Site-Specific, On-Demand trans-cranial, non-invasive stimulation of Deep Brain Stimulation for Quantitative EEG Method to specific brain regions, researchers have Enhancement of Memory Identify Individuals at Risk for demonstrated significant changes in blood Adverse Antidepressant Effects pressure and heart rate in physiological in Humans models. Researchers at UCLA have developed Antidepressant medication has an advanced surgical procedure that demonstrated efficacy for the symptoms UCLA Case No. 2011-737 utilizes electrical deep brain stimulation of depression, but some individuals may LEAD INVENTOR: Antonio A. F. De Salles with intracranial electrodes to enhance experience adverse effects on mood during Patent Status: Pending memory function. In controlled human antidepressant treatment that could result in experiments, the procedure confers harm to themselves or others. Researchers significant improvements in spatial learning at UCLA have developed a method that A Method for Deep Brain identifies patients likely to experience Stimulation Targeting Based on tasks. The researchers discovered specific brain regions that improve memory task adverse effects from antidepressant Brain Connectivity performance over others. The results of medication. A patient’s response to the Researchers at UCLA have developed these studies suggest that deep brain treatment is measured by using quantitative a method to more effectively place the stimulation is a highly translational and electroencephalographic recordings (QEEG). electrodes used in deep brain stimulation by efficacious approach to treating memory This method has been validated in a small using diffusion-tensor magnetic-resonance and cognition disturbances in a variety double-blind placebo-controlled clinical imaging (DTI) to customize the implantation of diseases. trial with 97% accuracy. Patient response protocol for each individual. This new to medication was corroborated by using method of precise targeting is based on UCLA Case No. 2011-330 standard clinical checklists that diagnose tractography (i.e., a procedure for visualizing LEAD INVENTOR: Itzhak Fried adverse symptoms. neural tracts) and uses DTI to map brain Patent Status: Pending UCLA Case No. 2006-262 connections in individual patients. Therefore, EVENT SPEAKER LEAD INVENTOR: Aimee Hunter the location of the most effective placement of the electrode can be identified for each Patent Status: U.S. Patent Issued individual. This methodology may also have #8,521,270 significant implications for targeting new regions in the brain that have poor internal anatomical definition using standard imaging.

UCLA Case No. 2011-700 LEAD INVENTOR: Nader Pouratian Patent Status: U.S. Patent Issued #9,220,458 EVENT SPEAKER

12 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Novel Application of Laser Unobstructing Microdevices Cardiovascular Devices Lithotripsy for Treating Vascular for Self-Clearing Implantable Calcification Catheters Method and Device for Traditionally, vascular bypass surgery has Implanted medical catheters are now an Continuous Non-Invasive been considered the “gold standard” of integral part of clinical care. However, many Blood Pressure Measurement treatment for peripheral arterial disease. chronically-implanted catheter systems Current methods to measure blood pressure However, surgery is associated with are plagued with reduced performance fall into two categories: sphygmomanometer significant morbidity and mortality, and 40% as a result of accumulating biological (inflatable cuff) or arterial line blood pressure of these patients are not eligible for surgery. debris. Dr. Jack Judy and colleagues in the monitor. Inflatable cuffs are non-invasive, Percutaneous Transluminal Angioplasty Department of Bioengineering at UCLA have but are prone to operator/device error (PTA) has been introduced as an alternative developed an unobstructing microdevice and yield single readings at the time of to surgical revascularization demonstrating for self-clearing catheters that alleviates measurement. On the other hand, arterial favorable clinical outcomes, but still flow obstruction. The researchers designed line blood pressure monitors provide real- carries its own limitations. To overcome micro-mechanical mechanisms to disrupt the time blood pressure monitoring but require the limitations of PTA, UCLA researchers accumulation of biological material and keep an invasive insertion through the skin into have developed a special endovascular catheter pores clear of debris. This device an artery, risking infection, arterial damage catheter that can be used for laser-assisted may be directly integrated into commercially and clotting. UCLA researchers have angioplasty under direct visualization. available catheter systems for use in designed a method and device that provides This method also allows for irrigation and existing surgical techniques (e.g. chronically non-invasive, continuous and accurate extraction of ablation-induced debris, thus implanted catheters). reducing the risk of distal embolization. blood pressure measurements by utilizing UCLA Case No. 2010-175 ultrasound technologies via an ultrasound This method is based on Holmium laser and LEAD INVENTOR: Jack Judy probe externally applied to the arm. provides a higher energy and repetition rate for smoother cutting and faster, more Patent Status: Pending UCLA Case No. 2015-899 efficient tissue ablation. Pub. No. US 2011/0313340 A1 LEAD INVENTOR: Dino Di Carlo UCLA Case No. 2012-565 Patent Status: Pending Dual Rotational Stent LEAD INVENTOR: Bashir Tafti Patent Status: Pending Researchers at UCLA invented a novel dual Improved Treatment of Pub. No. WO/2013/184697 rotational stent device for the endovascular Metabolic Acidosis treatment of cerebral aneurysm without the need for placing coils in the aneurysm Professors Thomas Mason and Jeffrey Novel Catheter for Precise lumen. The adjustable and variable struts Kraut in UCLA’s Department of Chemistry Stent Delivery density pattern of the new stent device and School of Medicine, respectively, allows it to cover the orifice of the aneurysm. have developed improved materials and Current therapeutic strategies for the This is advantageous for causing blockage methods of treating acute metabolic management of cerebrovascular disease of blood flow to the occluding aneurysm acidosis, a condition in which pH within a (CVD) include endovascular stents to expand while sparing blood flow to perforators or patient has become abnormally acidic and a narrowed or blocked artery. The flexible side branches near the aneurysm neck. can be life-threatening. The inventors have nature of the stent that permits expansion Specifically, the new compound stent has developed more effective base-treatment and enables passage through tortuous blood two main, but separate components; one for solutions involving a strong base, such as vessels also imposes a technical challenge, being positioned and stabilized in the parent disodium carbonate, mixed with a weak known as foreshortening, to the accurate vessel spanning the neck of the aneurysm, base, such as sodium bicarbonate to raise placement of the stent. Foreshortening and another for controlling the degree of both intracellular and extracellular pH while describes the change in length of the stent blood flow into the aneurysm. beneficially consuming dissolved carbon as it elongates to fit the confines of the delivery catheter and shortens following dioxide. Additionally, the investigators have UCLA Case No. 2009-668 its expansion within the target vessel— conceived new methods of delivering these LEAD INVENTOR: Dieter Enzmann formulations in a time- and spatially-varying leaving the surgeon to estimate precise Patent Status: Pending manner, thereby optimizing the solution’s placement. UCLA clinician Dr. Satoshi Pub. No. WO/2014/028913 mixing ratio and rate of delivery based Tateshima in the Division of Interventional on past and present measurements of a Neuroradiology has developed a novel patient’s blood-gas parameters, including pH. catheter to help anticipate the degree of foreshortening during stent deployment. The UCLA Case No. 2013-076 present technology overcomes the inherent LEAD INVENTOR: Thomas Mason limitations of the widely used braided and Patent Status: Pending laser cut stents—providing a superior device with increased placement accuracy and ease of use.

UCLA Case No. 2012-218 LEAD INVENTOR: Satoshi Tateshima Patent Status: Pending Pub. No. WO/2014/042900

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 13 Bioactive Endovascular Coils Method and Device for Treating Researchers at UCLA have developed Intracranial Vascular Aneurysms Device Materials a detachable endovascular coil system Inventors at UCLA have developed a with increased biological activity. These device, and a method, for the therapeutic Biodurable and Bioselective coil materials are inherently bioactive and management of intracranial vascular Coatings for Dental Implants can be further coated with, or act as a aneurysms. This technology involves the use The oral cavity is a complex ecosystem of delivery vehicle for, bioactive or therapeutic of intravascular catheters that can directly microbial organisms, some being harmful agents, such as drugs to control the image the aneurysm, and can occlude the and some beneficial. However, modern inflammatory reaction inside an aneurysm. entire lumen of the aneurysm sac using liquid medicine has introduced materials and The innovation maintains the mechanical sealing agents. The intracranial catheters implants that may disrupt the natural flexibility of the coils, ensuring that they are designed in various configurations so equilibrium and lead to oral health problems. are highly effective at preventing blood that they can be used to treat aneurysms UCLA researchers are developing a series flow. These improvements will accelerate regardless of their neck size or location of materials that prevent the attachment aneurysmal healing and minimize their rate within the intracranial vascular system. and growth of harmful bacteria, but allow of recurrence. UCLA Case No. 1996-528 selected neutral or beneficial flora to grow at endogenous levels; much like the normal UCLA Case No. 2011-135 LEAD INVENTOR: Tarik Massoud LEAD INVENTOR: Benjamin Wu environment of healthy oral cavities. The Patent Status: U.S. Patent Issued benefits of this new paradigm for oral Patent Status: Pending #5,776,097 healthcare are realized by new materials Pub. No. US 2014/0180395 A1 that support bio-beneficial and selective Neuro-Endovascular Ultrasound environments for preventative care, rather Brain Collateral Perfusion Thrombolysis than treating diseases after the fact. Augmentation by Cerebral Researchers at UCLA have developed a new Venous Pressure Modulation UCLA Case No. 2015-463 method of treating stroke using ultrasonic LEAD INVENTOR: Wenyuan Shi UCLA researchers have developed a novel energy. There are several advantages of Patent Status: Pending method and device to improve cerebral this method over conventional fibrinolytic blood flow to about 50% of normal baseline therapy: (1) ultrasound can recanalize arteries value, thereby treating acute or chronic much quicker than fibrinolytic therapy, UCLA Inventors Create ischemia associated with stroke. The device (2) ultrasound does not cause bleeding Platform Technology to Create and corresponding method uses applied complications, and (3) ultrasound can be Customizable Nanoscale Wound pressure to artificially achieve collateral more economical than fibrinolytic therapy in Management Tools circulation in the brain. To increase cerebral itself and in overall hospital costs. venous pressure and thereby, redirect UCLA researchers in the Departments of maldistributed blood flow, the device UCLA Case No. 1995-593 Chemistry, Physics, and Bioengineering, led creates an occlusion of one or more veins LEAD INVENTOR: Cheng Ji by Dr. Tim Deming of the Bioengineering coupled to the collapsed vessel. The device Patent Status: U.S. Patent Issued department, have developed a platform to consists of an elongated tubular member #6,024,718 create and modify nanoscale vesicles and with proximal and distal ends for insertion hydrogels for use in wound management. into a patient’s superior vena cava (or other The poly-peptide based platforms created vein), an expandable occluder located at by the Deming group are customizable in the distal end of the tubular member (the nearly all physical characteristics, can be occluder has an expanded and a collapsed tailored in size, be loaded with hydrophobic, state), a device to measure pressure at the hydrophilic, or cellular payloads, adaptable distal end of the tubular member, a device to to specific delivery locations, low toxicity, are measure cerebral blood flow in the patient, fully synthetic, possess highly reproducible and a controller programmed to actuate properties, and are inexpensive to prepare the expandable occluder as a function of compared to solid-phase peptide synthesis. the measured venous pressure and the The platform can be used to create novel, measured cerebral blood flow. need-based nanoscale vesicles or injectable hydrogels, and can be used to augment UCLA Case No. 2009-224 existing material systems. LEAD INVENTOR: David Liebeskind UCLA Case No. 2015-124 Patent Status: Pending LEAD INVENTOR: Timothy J. Deming Pub. No. US 2010/0318114 A1 Patent Status: Pending

14 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Poly(p-xylylene) Polymer-Based A Novel Polymer Platform for Surface Modification of Microfilms for Oral Delivery of Drug Delivery Endovascular Devices Therapeutics Aggressive surgical resection and Current endovascular procedures for the Poly(p-xylylene), trade name Parylene, is an chemoradiation therapy (CRT) are the treatment of vascular diseases use a number FDA-approved material used as a protective dominant treatment course for patients with of metallic devices including guidewires, coating for medical devices, but its elution Head and Neck Squamous Cell Carcinoma stents and coils. Although these materials capabilities in pharmaceuticals are less (HNSCC), but these approaches often are commonly used, they have several exploited. UCLA researchers have utilized negatively impact patient quality of life, limitations, such as friction generated during semi-porous poly(p-xylylene) film as a including disfiguration and loss of facial the installation procedure and the need stand-alone vehicle for the intraoral delivery mobility in some cases. UCLA researchers to be on blood thinning medication for a of pharmaceuticals with predetermined have developed a novel implantable drug long time after implantation. Researchers at time scales and dimensions. The film is delivery device that reproducibly reduces UCLA have discovered a method of treating synthesized as a semi-porous patch to be tumor growth in vivo, bypassing the NiTi, “nitinol,” sheets, wires, or stents that placed in the mouth for long-term (greater traditional HNSCC treatment course. The overcomes these limitations. The devices than 1 month) storage and delivery of technology combines biocompatible polymer are treated with a type of light, causing them therapeutic compounds. Due to the benign sheets with anti-tumor drugs and immune- to take on super hydrophilic properties. This synthesis process of the Parylene film, a boosting proteins that can be implanted conversion increases the affinity between variety of therapeutic compounds can be to the surgical bed after debulking of the the device and vascular tissue, resulting incorporated, including small molecule drugs tumor. These layers of sheets are highly in the acceleration of the healing process and proteins for anti-inflammatory, anti- customizable, as they can incorporate and a reduction in clotting. The hydrophilic cancer and anti-mucosal ulcer therapies. multiple drugs at different concentrations device also demonstrates less friction during and release rates. insertion and delivery. UCLA Case No. 2014-555 LEAD INVENTOR: Dean Ho UCLA Case No. 2014-235 UCLA Case No. 2008-007 Patent Status: Pending LEAD INVENTOR: Benjamin Wu LEAD INVENTOR: Satoshi Tateshima Patent Status: Pending Patent Status: U.S. Patent Issued Graphene Based Catalysts #8,487,284 for Biomimetic Generation of Bidirectional Hyperelastic Covers Antithrombotic Species for Woven Stents Improvement of Dental Resins: Decreased Toxicity and Improved Thrombogenicity (the tendency for blood Current stent designs frequently result to adhere to a material’s surface) has in hazardous wrinkling of the cover upon Biocompatibility remained a major challenge for implanted deployment, substantially increasing the risk Resin-based and resin-containing materials medical devices since their inception. of stent failure, and subsequent morbidity. are routinely used in dental practice as direct UCLA researchers from the Departments UCLA researchers have developed a novel filling materials, fissure sealing agents, and of Chemistry and Materials Science and hyperelastic thin film nitinol (HE-TFN) that as bonding resins or resin cements for metal, Engineering have developed a graphene- can be used to cover medical stents. This porcelain, resin inlays, veneers, crowns, and based catalyst for generating HNO, an porous film maintains a deformation ratio bridges. While the use of resin-containing antithrombogenic species, for biomedical that matches the commercial stent distortion materials is beneficial to the appearance applications. This material greatly extends during deployment. As a result, potentially of patients, these materials carry the risks the lifetime of antithrombogenicity by dangerous kinks and folds that arise from the of cytotoxicity and allergy often through using endogenous and abundant glucose crimping/expanding process are substantially resins such as HEMA or TEGDMA. UCLA and L-arginine for the production of HNO. avoided. This ensures the conformal stent investigators have discovered that the The graphene-based conjugates can be delivery and deployment. Furthermore, the presence of a chemical inhibitor (CI) can incorporated into polymer coatings that can design strategy and the hyperelastic material inhibit HEMA- and TEGDMA-mediated be applied to biomedical devices. allow customization of the cover to different apoptosis (cell death) in numerous human deformation ratios, making the novel cell lines. Not only was cell death inhibited, UCLA Case No. 2014-521 cover widely applicable to various types of but the presence of the CI also led to an LEAD INVENTOR: Xianfeng Duan commercial stents. increased viability and function of treated Patent Status: Pending cells. The results indicate that the CI UCLA Case No. 2013-238 prevents adverse effects mediated by HEMA, LEAD INVENTOR: Greg Carman TEGDMA and bleaching agents and may be Patent Status: Pending incorporated into additive resin materials.

UCLA Case No. 2005-379 LEAD INVENTOR: Anahid Jewett Patent Status: U.S. Patent Issued #8,481,005

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 15 A Device for In Vivo Diagnostic Tools Characterization of Body Fluids Orthopedic Devices and The rheological properties of certain Biomechanics Multi-Modal Depth-Resolved fluid reservoirs in the body, such as the Tissue Status Monitor vitreous humor of the eye, hold clinical Tendon-Driven Actuation Module Researchers at UCLA have developed a value for monitoring a variety of disorders for Robotic Hands portable tissue status monitor that sits on the as well as evaluating effects of therapeutic Researchers, led by Dr. Veronica J. Santos surface of the skin and can provide depth- treatments. However, no devices currently in the UCLA Biomechatronics Lab, have resolved information about tissue health exist to rapidly assess fluid properties developed a compact actuation module status, which is of paramount importance in humans in vivo. Dr. Pirouz Kavehpour, that can deliver fast, forceful, high-precision where tissue is very thin or consists of Professor in the Department of Mechanical control of any tendon-driven robotic multiple layers. The monitor uses a variety & Aerospace Engineering at UCLA, and manipulator. The design is based on a of sensors to perform not only near- colleagues have developed a needle-like rotary motor unit that can exert either uni- infrared spectroscopy, but also ultrasound, probe to directly quantify the rheological or bi-directional (“push-pull”) control of pressure, temperature and stretch sensing. properties of human body fluid in real time. any tendon-driven rotational joint, thereby In providing depth-resolved physiologic Dr. Kavehpour’s work has demonstrated enabling independent, high-performance information, the technology may be used to that the physical properties of human body control of each individual active degree of monitor tissue after vascular surgery, during fluid can be informative in determining freedom in a robotic hand, including a palmar prolonged surgeries, or after mastectomy. macromolecular structure and organization flexion degree of freedom. In addition, the device can fit easily under within an organ and that this information may be useful for detecting and monitoring surgical dressings or casts, and operates UCLA Case No. 2015-071 disease. This probe has the advantages of wirelessly, making it rather simple to use. LEAD INVENTOR: Veronica Santos being minimally-invasive and can measure UCLA Case No. 2013-527 fluid properties in vivo, obviating the need Patent Status: Pending LEAD INVENTOR: Warren Grundfest for fluid extraction. Thus, this device can be Pub. No. WO/2014/055753 Patent Status: Pending used to diagnose the risk or the presence of a degenerative or pathologic state through Objective, Real-Time Acoustic A Rectal Mucosa Sampling Tool measurement of body fluid. Measurement and Feedback for Proper Fit and Fill of Hip Implants Obtaining a sample of the rectal mucosa UCLA Case No. 2011-208 is key to millions of diagnostic procedures LEAD INVENTOR: Pirouz Kavehpour Orthopedic surgeons currently rely on performed each year, including those for Patent Status: Pending manual assessment of the fit of implants colorectal and cervical cancer. Physician- in bone, leaving the procedure prone scientists at the UCLA David Geffen School to technical errors that require revision Non-Invasive Optometric Medical surgeries. The present invention helps of Medicine have developed an improved Diagnostic Device device for sampling the rectal mucosa. improve implant fit by aiding surgeons’ The device design eliminates the need to UCLA researchers have created a fast, senses during the broaching procedure by completely insert the tube into the rectum. low-cost, and non-invasive approach for analyzing and classifying acoustic features This substantially reduces the discomfort diagnosing various skin-related diseases. generated from hammering the broach into associated with the procedure. In addition, The technology takes advantage of cancellous bone. The method monitors the other novel design implements make the tool the temporal response of endogenous impact between the femoral component of more efficient, more precise, and safer for fluorophores to a pulse of excitation light. a hip prosthesis with the patient’s femur. the patient. A non-invasive optometric device is used The impact data is decomposed by a data to measure skin autofluorescence which acquisition and analysis device. Metrics UCLA Case No. 2012-535 depends on the health of the patient. The based on a number of acoustic features are LEAD INVENTOR: Jonathan Braun optometric device can be used to diagnose calculated to determine the fit and stability of Patent Status: Pending any disease affecting the auto-fluorescence the broach in the femur. Results are classified of the skin. Examples include hyper- and output to a user interface to assist the pigmentation diagnosis of non-melanoma surgeon. skin cancer, photo-aging caused by UV, and UCLA Case No. 2014-935 monitoring utriculus. It can also be used to determine the depth and size of a cancerous LEAD INVENTOR: George Hafzalla lesion and changes in skin morphology. Patent Status: Pending The device could be used for—but is not limited to—monitoring diabetes, skin-related disorders, cancer, acne, and photo-aging.

UCLA Case No. 2004-657 LEAD INVENTOR: Laurent Pilon Patent Status: U.S. Patent Issued #7,904,140

16 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE A Novel Device for Quantifying Rotational Stability of the Knee Radiation Therapy and Sensors and Patient The current standard for determining anterior Oncology Monitoring Devices cruciate ligament (ACL) reconstruction effectiveness, the Lachman test, only A Breast Immobilization Device Non-Invasive System for measures translational stability. For rotational to Improve Radiation Therapy Classification of Individual’s stability, the pivot shift test is widely accepted, though it lacks an objective Dosimetry Intake means of quantification and current devices Breast setup and immobilization is a UCLA researchers have developed a method are large, fixed-position constructs that are difficult problem for external beam radiation for processing data from piezoelectric impractical for clinical use. Dr. Petrigliano therapy of breast cancers. A lack of setup sensors worn around the neck in order and colleagues in UCLA’s Department reproducibility with breast tissue results in to more accurately assess what foods an of Orthopaedic Surgery have developed sub-optimal dosimetry and tissue toxicity in individual has ingested. Algorithms are being a novel microelectromechanical system non-targeted, healthy tissues. Dr. Ke Sheng, refined that employ a spectrogram analysis (MEMS) gyroscope with specific software Associate Professor in UCLA’s Department of towards multiple piezoelectric sensor architecture to quantitatively assess both Radiation Oncology, has developed a novel data. This method could greatly improve rotational and linear stability of the knee. breast immobilization device that allows monitoring of food intake in an effort to Non-invasively applied to a patient’s for more comfortable support as well as a better meet weight management goals. lower extremity, it provides an objective robust radiation dosimetry improvement in UCLA Case No. 2015-108 measurement of the axial rotation of the breast tissue without the skin dose build-up tibia relative to the femur during the pivot effect that has plagued existing methods. LEAD INVENTOR: Majid Sarrafzadeh shift exam. The device is low-cost and modifiable for the Patent Status: Pending desired breast morphology. UCLA Case No. 2012-519 Wireless Remote Sensing of LEAD INVENTOR: Frank Petrigliano UCLA Case No. 2013-077 Changes in Fluid Filled Containers Patent Status: Pending LEAD INVENTOR: Ke Sheng Pub No. WO/2013/123263 Patent Status: Pending Trials of remote sensing of patient metrics, Pub. No. WO/2014/074602 such as blood pressure, have been successful in reducing hospital visits and Magnetic Resonance Imaging medical costs by increasing the accuracy and amount of data, while lowering the (MRI) Device for Improved High- amount of staff time necessary to take Dose-Rate (HDR) Brachytherapy the data. However, for accurate fluid Treatment Planning management, staff must measure and Internal radiation therapy (brachytherapy) analyze the fluids, their flow rates, and their involves the positioning of tiny, radiation- compositions in order to ensure quality emitting sources within tumor tissue by using care. UCLA researchers have developed delivery devices such as catheters, needles a novel device and method for continuous or other hollow conduits. Dr. Daniel Ennis, and dynamic monitoring of patient fluids. Dr. Jeffrey Demanes, and colleagues in This technology may extend beyond patient UCLA’s Department of Radiological Sciences fluids to other medium such as evaluation of have developed a device that allows for the air (air leaks) following lung surgery or injury effective imaging of the radiation-delivering that guide timely management of drainage catheter and the surrounding tissue. Under tubes. Wireless remote sensing technology MRI, the device can be detected with may quickly detect changes in fluid or air high contrast, thereby providing valuable measurements suggestive of complications positioning information of the treatment before or after surgery enabling earlier catheters relative to the tumor and normal discharge from the hospital and safer tissue. The device will allow optimal outpatient monitoring. positioning of the radiation source for the UCLA Case No. 2014-499 purpose of radiation therapy. This device has LEAD INVENTOR: Dieter Enzmann utility in visualizing catheter placement in the body where brachytherapy is the preferred Patent Status: Pending treatment strategy and where catheters are used as brachytherapy conduits.

UCLA Case No. 2012-546 LEAD INVENTOR: Daniel Ennis Patent Status: Pending

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 17 Prediction of Clinical Deterioration Method to Non-Invasively designs. It contains a novel noise reduction mechanism, making it the most sensitive Dr. Scott Hu at UCLA has developed a Determine Respiration Rate Using probe of its kind. These properties allow the method to predict clinical deterioration of Pressure Sensors detection of metabolites at the single cell patients, which could warn clinicians of UCLA researchers in the Department of level. Additionally, the probe has a planar impending clinical deterioration before its Electrical Engineering have developed configuration, making it ideally suited for occurrence. This predictive method is able a noninvasive method for measuring microfluidic chips used for diagnosis and to detect rare events of patient deterioration respiratory rate. Although not required, the prognosis. It is also made with an ultra with high sensitivity and improve results as system is intended to be used when the small detection region, 0.08 mm length more samples are entered. This method had patient is sleeping, either at home or in a by 0.05 mm width by 0.05 mm height, a positive predictive value that was 50% clinical setting. While the user is lying on top for samples of small volume and low greater than traditional statistical models. of the mattress embedded with pressure concentration (such as biological samples). It is currently being used to predict sepsis sensors, the system calculates and displays in leukemia patients, but is being adopted the breathing rate of the user, which can be UCLA Case No. 2012-550 to predict respiratory failure, myocardial used to identify irregular breathing patterns. LEAD INVENTOR: Louis Bouchard infarction and other common critical care Of particular note is that the system can Patent Status: Pending aliments. detect episodes of apnea and subsequently Pub. No. WO/2014/011937 UCLA Case No. 2014-445 alert a medical professional or caregiver. The graphical user interface developed as part LEAD INVENTOR: Scott Hu Corneal Hydration Sensing with of the invention provides several additional Patent Status: Pending features. THz Illumination Proper corneal hydration levels are critical BigFoot: Analysis, Monitoring, UCLA Case No. 2013-009 to maintaining optical vision. Researchers Tracking, and Sharing of LEAD INVENTOR: Majid Sarrafzadeh at UCLA have developed an imaging Biomedical Features of Human Patent Status: Pending system to detect corneal hydration levels Appendages by illuminating the cornea with low power, Networked Sensor Systems for low energy, terahertz (THz) frequency Many diabetic patients suffer from peripheral light and measuring the magnitude of the neuropathy, a disorder that results in Remote Patient Monitoring reflected THz signal. The system is capable the loss of sensation in their extremities. Current methods to monitor sleep require of resolving 0.18% changes in the water Individuals with this condition may develop patients to go to Sleep Monitor Centers concentration of the cornea in vivo and severe infections from sores on the soles with large electrophysiology, respiratory results suggest a ∼3x increase in dynamic of their feet without their knowledge, which measurement, and motion measurement range over ultrasound-based pachymetry. can lead to the loss of limbs. BigFoot uses systems. UCLA researchers have developed This system can be used for detecting customized software integrated with a an innovative Wearable-to-Enterprise inflammation, immune responses, edema, or commercial flatbed scanner that enables Sleep Monitoring System to serve the other disease in the cornea. easy image acquisition and analysis of feet market demand for Out of Center Sleep abnormalities. For patients that find checking Testing (OCST) in adult patients. This UCLA Case No. 2012-100 their feet difficult, this tool can easily monitor, technology combines monitoring, data LEAD INVENTOR: Martin Culjat track data and share image data in order archiving, reporting, usage assurance, Patent Status: U.S. Patent Issued to identify abnormalities early and prevent and subject guidance. The system is #8,690,331 complications. comprised of wearable head, chest, and leg units. These units contain sensors UCLA Case No. 2014-132 Exercise-Based Entertainment for airflow, electroencephalography Controller LEAD INVENTOR: Aydogan Ozcan (EEG), electrooculography (EOG), Copyright Status: Pending electrocardiography (ECG), respiratory effort To help combat childhood obesity, UCLA and rate, electromyogram (EMG), sleep time, researchers in the Department of Electrical motion, blood oxygen, auditory sensing, and Engineering have developed an exercise- actigraphy sensing measurements. based entertainment controller system. The system allows children to use entertainment UCLA Case No. 2013-008 appliances, such as the television or LEAD INVENTOR: William J. Kaiser computer, based on the amount of physical Patent Status: Pending activity they have done throughout the day, Pub. No. WO/2014/066059 recorded via a pedometer. When a child plugs the pedometer into their PC, the NMR Probe for Detection of software retrieves data from the pedometer, and allots a time budget for the child to Microstructures use entertainment appliances. When the Nuclear Magnetic Resonance (NMR) time budget is exhausted, the power spectroscopy is a widely-utilized method control module shuts off the corresponding for analyzing small molecule compositions. appliance via an RF signal. However, NMR sensitivity is too poor for diagnostic purposes and has limited UCLA Case No. 2009-496 its use to academic research. A key LEAD INVENTOR: Majid Sarrafzadeh component responsible for the sensitivity Patent Status: Pending is the NMR probe, which holds the sample Pub. No. US 2013/0090213 as it is inserted into the magnetic field. UCLA researchers developed an NMR probe with sensitivity superior to current

18 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE Covalt Uterine Removal System Organ Resuscitation Solution Surgical Tools When a hysterectomy is performed due to and System for Enhanced the presence of cervical cancer, the risk Liver Transplantation Percutaneous Catheter for Lung of causing cancer cells being pushed into Researchers in the Department of Surgery Assist Device neighboring tissue and possibly growing and UCLA Pfleger Liver Institute have into new malignant tumors is great. While Some patients with severe lung disease developed a novel solution and system specimen retrieval bags have been used need to be treated with ECMO systems that to minimize the tremendous degree in conjunction with uterine manipulators oxygenate the blood using extracorporeal, of ischemia and reperfusion injury (IRI) to avoid the spillage of cancer cells, some bedside machines. The currently used associated with liver transplantation. The studies have reported that spillage still catheters for ECMO systems suffer from invention serves to replenish exhausted occurs over 10% of the time. Dr. Cohen has two primary disadvantages: blood that nutrients and resuscitate the organ before designed a specimen retrieval bag that has already been oxygenated often gets revascularization. In a swine model, utilizes air compression technology and re-circulated through the system; and use of the novel solution and system attaches to the uterine manipulator in order the catheter’s strong dependence on demonstrated enhanced liver function and to further reduce the spillage of cancer cells position results in inefficiencies when a improved survival compared to conventional during hysterectomies and other tumor patient inevitably moves. Dr. Ardehali has approaches. This system may salvage removal processes. designed a catheter that overcomes these livers, deemed to have incurred severe inefficiencies in ECMO catheter design UCLA Case No. 2014-395 degree of ischemic injury and discarded, to transplantable organs. A solution and by having both more stability during use LEAD INVENTOR: Joshua Cohen and a better fluid flow design that reduces system to alleviate organ damage from IRI Patent Status: Pending re-circulation. would have significant consequences on patient outcomes as well as the availability of UCLA Case No. 2014-642 Image-Guided Irrigating transplantable organs. LEAD INVENTOR: Abbas Ardehali Suction Cannula for Removal of UCLA Case No. 2012-292 Patent Status: Pending Intracerebral Hemorrhage and LEAD INVENTOR: Johnny Hong Other Lesions Device for Creating Stoma with Patent Status: Pending Intracerebral hemorrhages (ICHs) are Pub. No. US 2014/0329221 Desired Characteristics potentially life-threatening conditions that An ostomy is the surgical process of occur when a blood vessel ruptures within A Video-Guided Chest Tube the brain and causes an accumulation creating an opening (i.e. stoma) between Insertion System a hollow organ and the skin. The opening of blood. Dr. Neil Martin at UCLA has can be used to treat certain diseases of designed a simple multifunctional cannula Dr. Robert Cameron, Professor of Clinical the digestive or urinary systems, or it can system for performing minimally invasive Cardiothoracic Surgery and Surgical be used to remove an organ. Currently, image-guided evacuation of ICHs. After Oncology in the Department of Surgery at the skin defect for an ostomy is created making a small burr hole in the skull, the UCLA, has designed a novel trocar system freehand by the surgeon using a knife or cannula system is inserted toward areas of that supports real-time visual monitoring of cutting electrocautery and often is irregularly localized bleeding to both evacuate excess chest tube placement. Thousands of chest shaped and inappropriately sized. Even blood and irrigate the wound site until tubes are placed annually into the pleural when a template is used to mark the defect, hemostasis is reestablished. With multiple space of patients who have excessive air intrinsic skin tension due to collagen fiber instrument adapters, this system is capable and/or fluid collapsing the lung. Currently, still introduces imperfection in the opening. of performing visual endoscope guidance, chest tube placement involves either an Physicians from UCLA Department of stereotactic image guidance, MRI image extremely painful “medieval” incision and Surgery conceptualized a device for creating guidance, and computerized tomography clamp technique or a trocar/dilator system, clean stomata that involves a circular saw image guidance. Additionally, Dr. Martin’s both of which are “blind” procedures and a mechanism for stretching the skin to instrument may be adapted to allow the use often leading to poor tube position, organ specific tension. The invention can tailor of a rotational clot or tissue fragmentation damage, and even death. Dr. Cameron’s to the appropriate size of the patient and device for hematomas with higher levels of device capitalizes on existing medical video the size of the hollow viscous. This easy- blood clotting. technology to provide real-time monitoring to-use instrument can assist in reliably and and guidance of anatomical position of the UCLA Case No. 2014-320 consistently creating optimal stoma. chest tube during placement. LEAD INVENTOR: Neil Martin UCLA Case No. 2014-597 Patent Status: Pending UCLA Case No. 2012-287 LEAD INVENTOR: Jonathan Sack LEAD INVENTOR: Robert Cameron Patent Status: Pending Patent Status: Pending

4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 19 Lung Isolation System Expandable Mechanical Researchers at UCLA have invented a Distension Device for Hollow novel system that achieves reliable lung Organ Growth isolation using a standard large bore single Short gut syndrome is a condition in lumen endotracheal tube, which maximizes which patients have insufficient length compatibility with other devices. The system of intestine to maintain normal digestion enables true dual lumen lung isolation/ and absorption. In the United States, over ventilation thus enabling all the benefits of 100,000 patients suffer from the disease both a double lumen tube and a bronchial each year. Researchers at UCLA have blocker (the current methods of treatment) developed a device to mechanically stretch without the downsides of either. It also out the intestine through the application incorporates a video visualization system, of longitudinal force. The device is made thus precluding the need for traditional of shape memory materials such as nickel- fiberoptic bronchoscopy. titanium or biocompatible polymers. During UCLA Case No. 2011-739 implantation, the device is collapsed to its minimum size, followed by deployment LEAD INVENTOR: Nir Hoftman into the intestinal tract via a push rod. The Patent Status: Pending structure then binds to a particular location, Pub. No. WO/2013/188845 and slowly expands over a period of several weeks. In doing so, it applies longitudinal Robotic Micro-Surgery System force, resulting in the lengthening of the Researchers at UCLA have developed a intestine. robotic system that performs complete UCLA Case No. 2009-227 micro-surgical procedures by exactly LEAD INVENTOR: Greg Carman mimicking the motion of a joystick Patent Status: Pending controlled by a surgeon. The system Pub. No. WO/2010/124126 incorporates multiple arms, which can be moved separately or in unison. Each arm holds a surgical instrument that is moved in real time, has high range of motion, and has access to a universal cartridge that facilitates connections for multiple utilities. The instrument precision is further refined by filtering and removing the natural tremor of the surgeon’s hand. Additionally, because micro-surgery requires the instrument to mechanically maintain a fixed-point of rotation at the site of penetration, the system incorporates an integrated tracking system that allows the robot to compensate for patient movement. The tracking system also triggers automatic termination in the event that the patient moves beyond a determined threshold.

UCLA Case No. 2009-300 LEAD INVENTOR: Tsu-Chin Tsao Patent Status: Pending Pub. No. WO/2011/088400

20 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE The UCLA Office of Intellectual Property and Industry Sponsored Research (OIP-ISR) would like to acknowledge our Industry Advisors for their guidance and support.

SPONSORS:

INDUSTRY PARTNERS:

MEDICAL

IN COORDINATION WITH:

O ceUCSB of Technology & Industry Alliances

HOSTED BY:

This project received support from the NIH NCATS UCLA CTSI grant number UL1TR000124 Connect

UCLA TechMatch Service

http://oip.ucla.edu/industry/techmatch

One of the best ways to keep up to date on emerging technologies from UCLA is via our TechMatch Service. Based on the technology interest areas you specify when you sign up, our office will then provide ongoing updates to you as new technologies arise that appear to match your interest areas.

Twitter @UCLAinventsO ce of Intellectual Property and Industry UCLA MonthlySponsored Newsletter Research www.UCLAinvents.com

O ce of Intellectual Property and Industry Sponsored Research

For Technology Licensing or Research Collaboration Inquiries please contact us: [email protected] 310-794-0558